Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Horizon Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named to the 2023 Fortune 100 Best Companies to Work For List
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc - Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Voting Results from Special Shareholder Meetings
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.